STAT3 relays a differential response to melanoma-associated NRAS mutations
Melanoma patients carrying an oncogenic NRAS mutation represent 20% of all cases and present worse survival, relapse rate and therapy response than patients with wild type NRAS or with BRAF mutations. Nevertheless, no efficient targeted therapy has emerged so far for this group of patients in compar...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2 January 2020
|
| In: |
Cancers
Year: 2020, Volume: 12, Issue: 1 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers12010119 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers12010119 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/12/1/119 
|
| Author Notes: | James Kim, Daniel Novak, Christos Sachpekidis, Jochen Utikal and Lionel Larribère |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1696242959 | ||
| 003 | DE-627 | ||
| 005 | 20230426182328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200427s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers12010119 |2 doi | |
| 035 | |a (DE-627)1696242959 | ||
| 035 | |a (DE-599)KXP1696242959 | ||
| 035 | |a (OCoLC)1341316831 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kim, James |d 1994- |e VerfasserIn |0 (DE-588)1209143569 |0 (DE-627)1696296269 |4 aut | |
| 245 | 1 | 0 | |a STAT3 relays a differential response to melanoma-associated NRAS mutations |c James Kim, Daniel Novak, Christos Sachpekidis, Jochen Utikal and Lionel Larribère |
| 246 | 3 | 0 | |a three |
| 264 | 1 | |c 2 January 2020 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.04.2020 | ||
| 520 | |a Melanoma patients carrying an oncogenic NRAS mutation represent 20% of all cases and present worse survival, relapse rate and therapy response than patients with wild type NRAS or with BRAF mutations. Nevertheless, no efficient targeted therapy has emerged so far for this group of patients in comparison with the classical combination of BRAF and MEK inhibitors for the patient group carrying a BRAF mutation. NRAS key downstream actors should therefore be identified for drug targeting, possibly in combination with MEK inhibitors. Here, we investigated the influence of different melanoma-associated NRAS mutations (codon 12, 13 or 61) on several parameters such as oncogene-induced senescence, cell proliferation, migration or colony formation in immortalized melanocytes and in melanoma cell lines. We identified AXL/STAT3 axis as a main regulator of NRASQ61–induced oncogene-induced senescence (OIS) and observed that NRASQ61 mutations are not only more tumorigenic than NRASG12/13 mutations but also associated to STAT3 activation. In conclusion, these data bring new evidence of the potential tumorigenic role of STAT3 in NRAS-mutant melanomas and will help improving current therapy strategies for this particular patient group. | ||
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a mutation | |
| 650 | 4 | |a NRAS | |
| 650 | 4 | |a oncogene-induced senescence | |
| 650 | 4 | |a STAT3 | |
| 700 | 1 | |a Sachpekidis, Christos |d 1983- |e VerfasserIn |0 (DE-588)1099707269 |0 (DE-627)858738651 |0 (DE-576)469338482 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 12(2020,1) Artikel-Nummer 119, 15 Seiten |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a STAT3 relays a differential response to melanoma-associated NRAS mutations |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:1 |g extent:15 |a STAT3 relays a differential response to melanoma-associated NRAS mutations |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers12010119 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/12/1/119 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200427 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1209143569 |a Kim, James |m 1209143569:Kim, James |d 60000 |e 60000PK1209143569 |k 0/60000/ |p 1 |x j | ||
| 998 | |g 1099707269 |a Sachpekidis, Christos |m 1099707269:Sachpekidis, Christos |d 50000 |e 50000PS1099707269 |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1696242959 |e 3637131943 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"2 January 2020","dateIssuedKey":"2020"}],"recId":"1696242959","name":{"displayForm":["James Kim, Daniel Novak, Christos Sachpekidis, Jochen Utikal and Lionel Larribère"]},"note":["Gesehen am 27.04.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1696242959"],"doi":["10.3390/cancers12010119"]},"physDesc":[{"extent":"15 S."}],"relHost":[{"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Cancers","title_sort":"Cancers"}],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"disp":"STAT3 relays a differential response to melanoma-associated NRAS mutationsCancers","note":["Gesehen am 27.05.2020"],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"issn":["2072-6694"],"zdb":["2527080-1"],"eki":["614095670"]},"part":{"year":"2020","extent":"15","volume":"12","text":"12(2020,1) Artikel-Nummer 119, 15 Seiten","issue":"1"},"pubHistory":["1.2009 -"],"recId":"614095670","origin":[{"publisher":"MDPI","dateIssuedDisp":"2009-","publisherPlace":"Basel","dateIssuedKey":"2009"}]}],"title":[{"title_sort":"STAT3 relays a differential response to melanoma-associated NRAS mutations","title":"STAT3 relays a differential response to melanoma-associated NRAS mutations"}],"person":[{"display":"Kim, James","role":"aut","family":"Kim","given":"James"},{"display":"Sachpekidis, Christos","role":"aut","family":"Sachpekidis","given":"Christos"}],"language":["eng"]} | ||
| SRT | |a KIMJAMESSASTAT3RELAY2202 | ||